Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | ADH5 | P11766 | 2/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5837987 | 0.91 | LMNA (0.49) | LMNAMAPTCYP11B1CYP11B2CYP19A1 | |
| Imidazole SCHEMBL10464054 | 0.87 | LMNA (0.45) | LMNAMAPTCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL3490259 | 0.84 | LMNA (0.63) | LMNAMAPTCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL12117429 | 0.84 | CYP11B1 (0.56) | LMNAMAPTCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL29495237 | 0.83 | LMNA (0.58) | LMNAMAPTCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL8338440 | 0.79 | NOTUM (0.58) | LMNAMAPTCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL5136657 | 0.79 | LMNA (0.49) | LMNAMAPTCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL1449607 | 0.79 | LMNA (0.58) | LMNAMAPTCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL6259515 | 0.79 | LMNA (0.58) | LMNAMAPTCYP11B1CYP11B2CYP19A1 | |
| SCHEMBL14259451 | 0.79 | LMNA (0.58) | LMNAMAPTCYP11B1CYP11B2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431592-B2 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| EP-2270008-B1 | 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors | NOVARTIS AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| US-20120207751-A1 | Imidazoquinolines as lipid kinase inhibitors | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2292617-B1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | NOVARTIS AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| EP-1888578-B9 | 2-METHYL-2-[4-(3-METHYL-2-OXO-8-QUINOLIN-3-YL-2,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLINYL)-PHENYL]PROPIONITRILE AS LIPID KINASE INHIBITOR | NOVARTIS AG (CH) | 2012-04-25 | — | — | EP | disclosed |
| EP-1888578-B1 | 2-METHYL-2-[4-(3-METHYL-2-OXO-8-QUINOLIN-3-YL-2,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLINYL)-PHENYL]PROPIONITRILE AS LIPID KINASE INHIBITOR | NOVARTIS AG (CH) | 2011-11-30 | — | — | EP | disclosed |
| US-20110251202-A1 | 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2011-10-13 | — | — | US | disclosed |
| US-7994170-B2 | 1,3-dihydro-imidazo[4,5-C]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2292617-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | Novartis AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| EP-2270008-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2005021510-A2 | BENZIMIDAZOLE C-2 HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054655-A1 | Benzimidazole C-2 heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| US-20040092514-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-13 | — | — | US | disclosed |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-04 | — | — | US | disclosed |
| US-4900839-A | SUBSTITUTED PHENYLPROPENAMIDES | PFIZER INC. (US) | 1990-02-13 | — | — | US | disclosed |
| US-4851526-A | ANTIARRYTHMIA, HYPOTENSIVE, ANTIISCHEMIC | SCHERING A.G. (DE) | 1989-07-25 | — | — | US | disclosed |
| US-4837334-A | Precursors to quinolone inotropic agents | PFIZER INC. (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0306440-A2 | 1-(4-substituted phenyl)-1H-imidazoles as cardiovascular agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-03-08 | — | — | EP | disclosed |
| US-4728653-A | CONGESTIVE HEART FAILURE | PFIZER INC. (US) | 1988-03-01 | — | — | US | disclosed |
| EP-0166533-A1 | Quinolone inotropic agents | Pfizer Limited (GB) | 1986-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120207751-A1 | Imidazoquinolines as lipid kinase inhibitors | PI4KA, PDPK1, PI4KB | LMNA 1973/4885MAPT 4472/4885CYP11B1 574/4885 |
| US-20050054655-A1 | Benzimidazole C-2 heterocycles as kinase inhibitors | CDK2, ERBB2, ABL1 | LMNA 3560/4885MAPT 4312/4885CYP11B1 2722/4885 |
| US-20040044203-A1 | Novel tyrosine kinase inhibitors | ABL1, YES1, FER | LMNA 4571/4885MAPT 4113/4885CYP11B1 851/4885 |
| US-20110251202-A1 | 1,3-Dihydro-imidazo[4,5-c]quinolin-2-ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | LMNA 4019/4885MAPT 3946/4885CYP11B1 470/4885 |
| US-20040092514-A1 | Novel tyrosine kinase inhibitors | ABL1, ERBB2, ROS1 | LMNA 4545/4885MAPT 4085/4885CYP11B1 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.